Austar Lifesciences Limited board of directors announced that the group is expected to record a substantial reduction of not less than 60% in consolidated profits attributable to the shareholders of the company for the six months ending June 30, 2015, as compared with the corresponding period in 2014, mainly attributable to: delay in recognition of revenue due to subsequent modification of users requirements for projects undertaken by the Group during the past few months; and decrease in gross profit margin for certain projects undertaken by the Group.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8 HKD | -4.76% | -6.98% | -48.72% |
26/03 | Austar Lifesciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
22/01 | Austar Lifesciences to Swing to Loss; Shares Drop | MT |
1st Jan change | Capi. | |
---|---|---|
-48.72% | 52.49M | |
-5.56% | 181B | |
-0.11% | 108B | |
-6.17% | 66.12B | |
+2.64% | 50.65B | |
+6.58% | 43.11B | |
+4.91% | 41.3B | |
+21.98% | 31.6B | |
+14.45% | 25.03B | |
-5.81% | 24.16B |
- Stock Market
- Equities
- 6118 Stock
- News Austar Lifesciences Limited
- Austar Lifesciences Limited Provides Earnings Guidance for the Six Months Ending June 30, 2015